Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company's product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza; and SCB-219M, a thrombocytopenia receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, the company sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People's Republic of China.
Frequently asked questions
What sector does Clover Biopharmaceuticals Ltd (2197) operate in?
Clover Biopharmaceuticals Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Clover Biopharmaceuticals Ltd (2197) current stock price?
As of the latest data, Clover Biopharmaceuticals Ltd stock price is HK$1.97, with a previous close of HK$1.95. Clover Biopharmaceuticals Ltd gained HK$0.02 in the last trading session, representing a 1.03% increase.
What is Clover Biopharmaceuticals Ltd (2197) current market capitalization?
Clover Biopharmaceuticals Ltd market cap is approximately 2.55 billion.
What is Clover Biopharmaceuticals Ltd (2197) EBITDA?
Clover Biopharmaceuticals Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -128.70 million.
Does Clover Biopharmaceuticals Ltd (2197) pay dividends?
No. Clover Biopharmaceuticals Ltd does not pay a dividend.
What is Clover Biopharmaceuticals Ltd (2197) beta (volatility) score?
Clover Biopharmaceuticals Ltd has a beta of 2.570, indicating very high volatility compared to the market.
